Ranking vaccines: A prioritization framework: Phase I: Demonstration of concept and a software blueprint

Ranking Vaccines: A Prioritization Framework: Phase I: Demonstration of Concept and a Software Blueprint

Volumn , Issue , 2012, Pages 1-188

  Madhavan, Guruprasad ^a,b   Sangha, Kinpritma ^a   Phelps, Charles ^c,d,e,f   Fryback, Dennis ^g   Lieu, Tracy ^h   Martinez, Rose Marie ^a   King, Lonnie ⁱ  

^a Institute of Medicine   (United States)

^b NATIONAL ACADEMY OF SCIENCES   (United States)

^c UNIVERSITY OF ROCHESTER   (United States)

^d VirtualScopics Inc   (United States)

^e GILEAD SCIENCES   (United States)

^f CardioDx   (United States)

^g UNIVERSITY OF WISCONSIN MADISON   (United States)

^h HARVARD MEDICAL SCHOOL   (United States)

ⁱ OHIO STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 85018619410     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.17226/13382     Document Type: Book

References (68)

1. Andrus, J. K., V. Dietz, J. W. Fitzsimmons, and C. Castillo-Solorzano. 2006. Accelerating policy, deployment, and access to new and underutilized vaccines in developing countries. Harvard Health Policy Review 7(2):91-101.
2. Andrus, J. K., C. M. Toscano, M. Lewis, L. Oliveiria, A. M. Ropero, M. Dávila, and J. W. Fitzsimmons. 2007. A model for enhancing evidence-based capacity to make informed policy decisions on the introduction of new vaccines in the Americas: PAHO's ProVac initiative. Public Health Reports 122(6):811-816.
3. Barron, F. H., and B. E. Barrett. 1996. The efficacy of SMARTER: Simple multi-attribute rating technique extended to ranking. Acta Psychologica 93(1-3):23-36.
4. Berry, D. A., K. A. Cronin, S. K. Plevritis, D. G. Fryback, L. Clarke, M. Zelen, J. S. Mandelblatt, A. Y. Yakovlev, J. D. F. Habbema, and E. J. Feuer. 2005. Effect of screening and adjuvant therapy on mortality from breast cancer. New England Journal of Medicine 353(17):1784-1792.
5. Braithwaite, R., D. Meltzer, J. King Jr, D. Leslie, and M. S. Roberts. 2008. What does the value of modern medicine say about the $50,000 per quality-adjusted life-year decision rule? Medical Care 46(4):349-356.
6. Burchett, H. E. D., S. Mounier-Jack, U. K. Griffiths, and A. J. Mills. 2011. National decision-making on adopting new vaccines: A systematic review. Health Policy and Planning 27(Suppl 2):ii62-ii76.
7. Commission on Macroeconomics and Health. 2001. Macroeconomics and health: Investing in health for economic development. Report of the Commission on Macroeconomics and Health. Available at http://whqlibdoc. who.int/publications/2001/924154550x.pdf (accessed April 16, 2012).
8. Daniels, N. 2007. Just health: Meeting health needs fairly. Cambridge: Cambridge University Press.
9. Dyer, J. 1990. Remarks on the analytic hierarchy process. Management Science 36:249-258.
10. Edwards, W. 1979. Multiattribute utility measurement: Evaluating desegregation plans in a highly political context. In Evaluating interventions: Pros and cons, edited by R. Perloff. Beverly Hills, CA: Sage. Pp. 13-54.
11. Edwards, W., and F. H. Barron. 1994. SMARTS and SMARTER: Improved simple methods for multiattribute utility measurement. Organizational Behavior and Human Decision Processes 60(3):306-325.
12. Edwards, W. and J. R. Newman. 1982. Multiattribute evaluation. Beverly Hills, CA: Sage.
13. Epstein, J. M., J. Parker, D. Cummings, and R. A. Hammond. 2008. Coupled contagion dynamics of fear and disease: Mathematical and computational explorations. PLoS One 3(12):e3955.
14. Feeny, D., G. Torrance, and W. Furlong. 1996. Health Utilities Index. In Quality of life and pharmacoeconomics in clinical trials, 2nd ed., edited by B. Spilker. Philadelphia: Lippincott-Raven Press. Pp. 239-252.
15. Fenwick, E., K. Claxton, and M. Sculpher. 2001. Representing uncertainty: The role of cost-effectiveness acceptability curves. Health Economics 10(8):779-787.
16. Field, R. I., and A. L. Caplan. 2012. Evidence-based decision making for vaccines: The need for an ethical foundation. Vaccine 30(6):1009-1013.
17. Fox-Rushby, J. A., and K. Hanson. 2001. Calculating and presenting disability adjusted life years (DALYs) in cost-effectiveness analysis. Health Policy Plan 16(3):326-331.
18. Fryback, D. G. 2009. United States National Health Measurement Study, 2005-2006. In [Computer file]. National Archive of Computerized Data on Aging: Inter-University Consortium for Political and Social Research.
19. Fryback, D. G., N. C. Dunham, M. Palta, J. Hanmer, J. Buechner, D. Cherepanov, S. Herrington, R. D. Hays, R. M. Kaplan, and T. G. Ganiats. 2007. U.S. norms for six generic health-related quality-of-life indexes from the National Health Measurement Study. Medical Care 45(12):1162-1170.
20. Fryback, D. G., M. Palta, D. Cherepanov, D. Bolt, and J. S. Kim. 2010. Comparison of 5 health-related quality-of-life indexes using item response theory analysis. Medical Decision Making 30(1):5-15.
21. Garber, A., and C. Phelps. 1997. Economic foundations of cost-effectiveness analysis. Journal of Health Economics 16(1):1-31.
22. Gates, B. 2010. The decade of vaccines. In The Financial Times Blog, http:// tinyurl.com/6o7fd92 (accessed March 1, 2012).
23. GAVI Alliance. 2010. Investing in immunisation through the GAVI alliance: The evidence base. Geneva: GAVI Alliance.
24. Gold, M. R., D. L. Patrick, G. W. Torrance, D. G. Fryback, D. C. Hadorn, M. S. Kamlet, N. Daniels, and M. C. Weinstein. 1996. Identifying and valuing outcomes. In Cost effectiveness in health and medicine, edited by M. R. Gold, J. E. Siegel, L. B. Russell, and M. C. Weinstein. New York: Oxford University Press. Pp. 82-134.
25. Gold, M. R., D. Stevenson, and D. G. Fryback. 2002. HALYs and QALYs and DALYs, Oh my: Similarities and differences in summary measures of population health. Annual Review of Public Health 23(1):115-134.
26. Government of India. 2011. National vaccine policy. New Delhi: Ministry of Health and Family Welfare.
27. Greco, M., and L. Hessel. 2008. Development and supply of vaccines: An industry perspective. In New generation vaccines, 4th ed., edited by M. Levine, G. Dougan, M. Good, M. Liu, G. Nabel, J. Nataro and R. Rappuoli. New York: Informa Healthcare. Pp. 79-90.
28. HHS (U.S. Department of Health and Human Services). 2011. 2010 National vaccine plan. Washington, DC: U.S. Department of the Health and Human Services.
29. IOM (Institute of Medicine). 1985. New vaccine development: Establishing priorities. Volume I, diseases of importance in the United States. Washington, DC: National Academy Press.
30. IOM. 1986. New vaccine development: Establishing priorities. Volume II, diseases of importance in developing countries. Washington, DC: National Academy Press.
31. IOM. 2000. Vaccines for the 21st century: A tool for decisionmaking. Washington, DC: National Academy Press.
32. Jefferson, T. 1806. A tribute of gratitude: To Edward Jenner. In Thomas Jefferson: Letters 1743-1826. Charlottesville, VA: Electronic Text Center, University of Virginia Library.
33. Jenner, E. 1801. On the origin of the vaccine inoculation. London: D.N. Shury.
34. Keefer, D. L., C. W. Kirkwood, and J. L. Corner. 2004. Perspective on decision analysis applications, 1990-2001. Decision Analysis 1(1):4-22.
35. Keeler, E. B., and S. Cretin. 1983. Discounting of life-saving and other nonmonetary effects. Management Science 29(3):300-306.
36. Keeney, R., and H. Raiffa. 1976. Decisions with multiple objectives: Preferences and value tradeoffs. New York: John Wiley & Sons, Inc.
37. Keeney, R., and G. Smith. 1982. Structuring objectives for evaluating possible nuclear material control and accounting regulations. IEEE Transactions on Systems, Man and Cybernetics 12(6):743-750.
38. Keeney R, and D. von Winterfeldt. 2007. Practical value models. In Advances in decision analysis, edited by W. Edwards, R. F. Miles, and D. von Winterfeldt. New York: Cambridge University Press. Pp. 232-252.
39. Keeney, R., and D. von Winterfeldt. 2011. A value model for evaluating homeland security decisions. Risk Analysis 31(9):1470-1487.
40. Keeney, R., T. McDaniels, and V. Ridge-Cooney. 1996. Using values in planning wastewater facilities for metropolitan seattle. Journal of the American Water Resources Association 32(2):293-303.
41. Keja, K., C. Chan, G. Hayden, and R. H. Henderson. 1988. Expanded programme on immunization. World Health Statistics Quarterly. Rapport Trimestriel de Statistiques Sanitaires Mondiales 41(2):59-63.
42. Knutti, R., R. Furrer, C. Tebaldi, J. Cermak, and G. A. Meehl. 2010. Challenges in combining projections from multiple climate models. Journal of Climate 23(10):2739-2758.
43. Krantz, D. L, D. Luce, P. Suppes, A. Tversky, 1971. Foundations of Measurement, New York: Academic Press.
44. Luo, N., J. A. Johnson, J. W. Shaw, D. Feeny, and S. J. Coons. 2005. Selfreported health status of the general adult U.S. population as assessed by the EQ-5D and Health Utilities Index. Medical Care 43(11):1078-1086.
45. Luo, N., J. A. Johnson, J. W. Shaw, and S. J. Coons. 2009. Relative efficiency of the EQ-5D, HUI2, and HUI3 index scores in measuring health burden of chronic medical conditions in a population health survey in the United States. Medical Care 47(1):53-60.
46. Manning, W. G., D. Fryback, and M. Weinstein. 1996. Reflecting uncertainty in cost-effectiveness analysis. In Cost-effectiveness in health and medicine, edited by M. R. Gold, J. E. Siegel, L. B. Russell and M. C. Weinstein. New York: Oxford University Press. Pp. 247-275.
47. Mathers, C. D., A. D. Lopez, and C. J. L. Murray. 2006. The burden of disease and mortality by condition: Data, methods, and results for 2001. In Global burden of disease and risk factors, edited by A. D. Lopez, C. D. Mathers, M. Ezzati, D. T. Jamison, and C. J. L. Murray. Washington, DC: World Bank. Pp. 45-93.
48. McNeil, D. 2012. Bill Gates donates $750 million to shore up diseasefighting fund. New York Times, January 26.
49. Meckley, L. M., D. Greenberg, J. T. Cohen, and P. J. Neumann. 2010. The adoption of cost-effectiveness acceptability curves in cost-utility analyses. Medical Decision Making 30(3):314-319.
50. Molinari, N. A., I. R. Ortega-Sanchez, M. L. Messonnier, W. W. Thompson, P. M. Wortley, E. Weintraub, and C. B. Bridges. 2007. The annual impact of seasonal influenza in the US: Measuring disease burden and costs. Vaccine 25(27):5086-5096.
51. Murray, C. J. L., and A. D. Lopez. 1996. The global burden of disease: A comprehensive assessment of mortality and disability from diseases, injuries, and risk factors in 1990 and projected to 2020. Vol. 1, Global burden of disease and injury series. Cambridge, MA: Harvard School Public Health/WHO/World Bank.
52. Murray, C. J. L., and A. D. Lopez. 2000. Progress and directions in refining the global burden of disease approach: A response to Williams. Health Economics 9(1):69-82.
53. Phelps, C. E., and A. I. Mushlin. 1988. Focusing technology assessment using medical decision theory. Medical Decision Making 8(4):279-289.
54. Plotkin, S., S. Sepe, and M. Myers. 2000. Institute of Medicine report: "Vaccines for the 21st century," analysis and action plan for the National Vaccine Advisory Committee; prepared for NVAC Subcommittee on Future Vaccines. http://www.hhs.gov/nvpo/nvac/vaccines21cer.html (accessed January 26, 2012).
55. Poland, G. A., and E. K. Marcuse. 2011. Developing vaccine policy: Attributes of "just policy" and a proposed template to guide decision and policy making. Vaccine 29(44):7577-7578.
56. Ramsey, S., R. Willke, A. Briggs, R. Brown, M. Buxton, A. Chawla, J. Cook, H. Glick, B. Liljas, D. Petitti, and S. Reed. 2005. Good research practices for cost-effectiveness analysis alongside clinical trials: The ISPOR RCT-CEA Task Force Report. Value Health 8(5):521-533.
57. Rappuoli, R., and A. Aderem. 2011. A 2020 vision for vaccines against HIV, tuberculosis and malaria. Nature 473(7348):463-469.
58. Rappuoli, R., H. Miller, and S. Falkow. 2002. The intangible value of vaccination. Science 297(5583):937-939.
59. Rappuoli, R., C. Mandl, S. Black, and E. De Gregorio. 2011. Vaccines for the twenty-first century society. Nature Reviews Immunology 11(12): 865-872.
60. Rardin, R. 1997. Optimization in operations research. Upper Saddle River, NJ: Prentice Hall.
61. Saaty, T., 1987. Concepts, theory and techniques: Rank generation, preservation, and reversal in the Analytic Hierarchy Process. Decision Sciences 18:157-177.
62. Stern, A., and H. Markel. 2005. The history of vaccines and immunization: Familiar patterns, new challenges. Health Affairs 24(3):611-621.
63. von Winterfeldt, D., and W. Edwards. 1986. Decision analysis and behavioral research. Vol. 1. New York: Cambridge University Press.
64. Weinstein, M. C. 2008. How much are Americans willing to pay for a quality-adjusted life year? Medical Care 46(4):343-345.
65. WHO (World Health Organization). 2003. Making choices in health: WHO guide to cost-effectiveness analysis. Edited by T. Tan-Torres Edejer, R. Baltussen, T. Adam, R. Hutubessy, A. Acharya, D. B. Evans, and C. J. L. Murray. Geneva: World Health Organization.
66. WHO. 2004. Global burden of disease 2004 update: Disability weights for diseases and conditions. Geneva: World Health Organization.
67. WHO. 2006. Global immunization vision and strategy. www.who.int/immunization/ givs/en/index.html.
68. WHO. 2010. The Initiative for Vaccine Research, strategic plan 2010-2020. Geneva: Initiative for Vaccine Research, Department of Immunization, Vaccines and Biologicals.